← Back to Search

HCP-Guided Exercise for Pancreatic Cancer

N/A

Recruiting

Led By Paul Oberstein, MD

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Pathologically confirmed pancreatic cancer

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, final study visit (between weeks 2-4)

Awards & highlights

Study Summary

This trialtested if it's possible to safely add exercise to pre-surgery care for pancreatic cancer patients.

Who is the study for?

This trial is for adults over 18 with pathologically confirmed pancreatic cancer, who are candidates for pre-surgery therapy followed by surgery aimed at curing. They must be able to do physical activity and agree to blood draws and tissue collection. It's not for pregnant individuals, those in other conflicting trials, lacking consent capacity, with metastatic disease or recent injuries/surgeries that limit exercise.Check my eligibility

What is being tested?

The study tests a health care provider guided exercise program before surgical removal of pancreatic cancer. Participants will engage in this program for 2-4 weeks after their last neoadjuvant therapy and before surgery to assess the feasibility of such an intervention.See study design

What are the potential side effects?

Since the intervention involves exercise training, potential side effects may include typical risks associated with physical activity such as muscle strain or injury. However, specific side effects will depend on individual health conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer diagnosis is confirmed to be pancreatic.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, final study visit (between weeks 2-4)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, final study visit (between weeks 2-4)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, final study visit (between weeks 2-4) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Intervention Arm Participants in Compliance with HCP Exercise Intervention

Secondary outcome measures

Average Daily MET Rates

Change in Number of Circulating CD8-Positive T Cells Expressing IL-15Ra as Assessed by Flow Cytometry

Change in Number of Tumor-Infiltrating CD8-Positive T Cells

+9 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: HCP-Guided ExerciseExperimental Treatment1 Intervention

Participants will schedule twice-weekly in-person visits to conduct health care provider (HCP)-supervised exercise activity for a minimum of 30 minutes. At least 3 additional times per week, participants will conduct self-directed exercise at home. Activity and other outcomes will be monitored with an Actigraph Centrepoint Insight Watch. The HCP guided therapy will continue on a weekly basis for at least 2 weeks and up to a maximum of 4 weeks.

Group II: ControlActive Control1 Intervention

Participants will not participate in the HCP-guided exercise intervention but will wear the Actigraph Centrepoint Insight Watch.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor

1,368 Previous Clinical Trials

839,709 Total Patients Enrolled

Paul Oberstein, MDPrincipal InvestigatorNYU Langone Medical Center

2 Previous Clinical Trials

95 Total Patients Enrolled

Media Library

HCP-Guided Exercise Training Program Clinical Trial Eligibility Overview. Trial Name: NCT05483075 — N/A

Pancreatic Cancer Research Study Groups: Control, HCP-Guided Exercise

Pancreatic Cancer Clinical Trial 2023: HCP-Guided Exercise Training Program Highlights & Side Effects. Trial Name: NCT05483075 — N/A

HCP-Guided Exercise Training Program 2023 Treatment Timeline for Medical Study. Trial Name: NCT05483075 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What characteristics render someone a viable candidate for this clinical trial?

"To be eligible for this medical trial, subjects must have a diagnosis of malignant pancreatic neoplasm and fall in the age range of 18 to 90. A maximum enrolment limit of 30 patients has been set for this study."

Answered by AI

Is there still capacity for enrollment in this investigation?

"Affirmative. The information available from clinicaltrials.gov indicates that this medical trial, which was initially posted on November 15th 2022 is currently seeking participants. This study requires 30 people to join at a single site."

Answered by AI

Are there age restrictions on enrolment in this clinical investigation?

"Individuals aged 18 and above, but younger than 90 years old may participate in this study."

Answered by AI

What is the current size of the patient cohort participating in this research study?

"Affirmative. The clinical trial is actively recruiting, as indicated on the information shared through clinicaltrials.gov. It was first published on November 15th 2022 and modified on November 23rd 2022; it requires 30 participants to be recruited from a single site in order to proceed with its research goals."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer

2022. "Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05483075.